| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. | Gynecol Oncol | 2004 | 2.42 |
| 2 | A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. | Invest New Drugs | 2002 | 0.92 |
| 3 | Allometric scaling of pegylated liposomal anticancer drugs. | J Pharmacokinet Pharmacodyn | 2011 | 0.90 |
| 4 | A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. | Oncologist | 2007 | 0.83 |
| 5 | Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. | J Thorac Oncol | 2012 | 0.82 |